Literature DB >> 15383144

HIV-1 Vif and APOBEC3G: multiple roads to one goal.

Joao Goncalves1, Mariana Santa-Marta.   

Abstract

The viral infectivity factor, Vif, of human immunodeficiency virus type 1, HIV-1, has long been shown to promote viral replication in vivo and to serve a critical function for productive infection of non-permissive cells, like peripheral blood mononuclear cells (PBMC). Vif functions to counteract an anti-retroviral cellular factor in non-permissive cells named APOBEC3G. The current mechanism proposed for protection of the virus by HIV-1 Vif is to induce APOBEC3G degradation through a ubiquitination-dependent proteasomal pathway. However, a new study published in Retrovirology by Strebel and colleagues suggests that Vif-induced APOBEC3G destruction may not be required for Vif's virus-protective effect. Strebel and co-workers show that Vif and APOBEC3G can stably co-exist, and yet viruses produced under such conditions are fully infectious. This new result highlights the notion that depletion of APOBEC3G is not the sole protective mechanism of Vif and that additional mechanisms exerted by this protein can be envisioned which counteract APOBEC3G and enhance HIV infectivity.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15383144      PMCID: PMC521195          DOI: 10.1186/1742-4690-1-28

Source DB:  PubMed          Journal:  Retrovirology        ISSN: 1742-4690            Impact factor:   4.602


  49 in total

Review 1.  Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity.

Authors:  M Karin; Y Ben-Neriah
Journal:  Annu Rev Immunol       Date:  2000       Impact factor: 28.527

Review 2.  Mechanisms underlying ubiquitination.

Authors:  C M Pickart
Journal:  Annu Rev Biochem       Date:  2001       Impact factor: 23.643

3.  Hypermutation of HIV-1 DNA in the absence of the Vif protein.

Authors:  Denise Lecossier; Francine Bouchonnet; François Clavel; Allan J Hance
Journal:  Science       Date:  2003-05-16       Impact factor: 47.728

4.  DNA deamination mediates innate immunity to retroviral infection.

Authors:  Reuben S Harris; Kate N Bishop; Ann M Sheehy; Heather M Craig; Svend K Petersen-Mahrt; Ian N Watt; Michael S Neuberger; Michael H Malim
Journal:  Cell       Date:  2003-06-13       Impact factor: 41.582

5.  Cellular and viral specificities of human immunodeficiency virus type 1 vif protein.

Authors:  N Madani; D Kabat
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

6.  Role of Vif in stability of the human immunodeficiency virus type 1 core.

Authors:  A Ohagen; D Gabuzda
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

7.  A role for ubiquitin ligase recruitment in retrovirus release.

Authors:  B Strack; A Calistri; M A Accola; G Palu; H G Gottlinger
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

8.  Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein.

Authors:  Ann M Sheehy; Nathan C Gaddis; Jonathan D Choi; Michael H Malim
Journal:  Nature       Date:  2002-07-14       Impact factor: 49.962

9.  Human immunodeficiency virus type 1 Vif is efficiently packaged into virions during productive but not chronic infection.

Authors:  Sandra Kao; Hirofumi Akari; Mohammad A Khan; Markus Dettenhofer; Xiao-Fang Yu; Klaus Strebel
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  Production of infectious human immunodeficiency virus type 1 does not require depletion of APOBEC3G from virus-producing cells.

Authors:  Sandra Kao; Eri Miyagi; Mohammad A Khan; Hiroaki Takeuchi; Sandrine Opi; Ritu Goila-Gaur; Klaus Strebel
Journal:  Retrovirology       Date:  2004-09-17       Impact factor: 4.602

View more
  10 in total

1.  Feline lentivirus evolution in cross-species infection reveals extensive G-to-A mutation and selection on key residues in the viral polymerase.

Authors:  Mary Poss; Howard A Ross; Sally L Painter; David C Holley; Julie A Terwee; Sue Vandewoude; Allen Rodrigo
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

2.  On the solution conformation and dynamics of the HIV-1 viral infectivity factor.

Authors:  Sean R Marcsisin; Purushottam S Narute; Lori A Emert-Sedlak; Marek Kloczewiak; Thomas E Smithgall; John R Engen
Journal:  J Mol Biol       Date:  2011-07-29       Impact factor: 5.469

Review 3.  Emerging complexities of APOBEC3G action on immunity and viral fitness during HIV infection and treatment.

Authors:  Mahdis Monajemi; Claire F Woodworth; Jessica Benkaroun; Michael Grant; Mani Larijani
Journal:  Retrovirology       Date:  2012-04-30       Impact factor: 4.602

4.  APOBEC3B Potently Restricts HIV-2 but Not HIV-1 in a Vif-Dependent Manner.

Authors:  Susana Bandarra; Eri Miyagi; Ana Clara Ribeiro; João Gonçalves; Klaus Strebel; Isabel Barahona
Journal:  J Virol       Date:  2021-09-15       Impact factor: 5.103

Review 5.  Current perspectives on HIV-1 antiretroviral drug resistance.

Authors:  Pinar Iyidogan; Karen S Anderson
Journal:  Viruses       Date:  2014-10-24       Impact factor: 5.048

6.  The dimerization domain of HIV-1 viral infectivity factor Vif is required to block virion incorporation of APOBEC3G.

Authors:  James H Miller; Vlad Presnyak; Harold C Smith
Journal:  Retrovirology       Date:  2007-11-24       Impact factor: 4.602

Review 7.  Evasion of adaptive immunity by HIV through the action of host APOBEC3G/F enzymes.

Authors:  Michael Grant; Mani Larijani
Journal:  AIDS Res Ther       Date:  2017-09-12       Impact factor: 2.250

Review 8.  A Novel Regulator of Activation-Induced Cytidine Deaminase/APOBECs in Immunity and Cancer: Schrödinger's CATalytic Pocket.

Authors:  Justin J King; Mani Larijani
Journal:  Front Immunol       Date:  2017-04-06       Impact factor: 7.561

Review 9.  Post-translational Modification-Based Regulation of HIV Replication.

Authors:  Lin Chen; Oliver T Keppler; Christian Schölz
Journal:  Front Microbiol       Date:  2018-09-11       Impact factor: 5.640

10.  Development of Lentiviral Vectors Simultaneously Expressing Multiple siRNAs Against CCR5, vif and tat/rev Genes for an HIV-1 Gene Therapy Approach.

Authors:  Francesca Spanevello; Arianna Calistri; Claudia Del Vecchio; Barbara Mantelli; Chiara Frasson; Giuseppe Basso; Giorgio Palù; Marina Cavazzana; Cristina Parolin
Journal:  Mol Ther Nucleic Acids       Date:  2016-04-19       Impact factor: 10.183

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.